조영민 박사

(MD, PhD)

Young Min Cho, MD, PhD

Dr. Young Min Cho received his MD (1996) and PhD (2004) degrees from Seoul National University College of Medicine, where he also completed his residency and fellowship training in endocrinology and metabolism at Seoul National University Hospital (SNUH). He was appointed Instructor in the Division of Endocrinology and Metabolism in 2003 and has since built his career as a clinician, researcher, and educator dedicated to advancing the field.

From 2009 to 2010, Dr. Cho served as a Visiting Scholar at the University of British Columbia, Canada, where he focused on gastrointestinal endocrinology. This experience enriched his expertise in gut hormones and broadened his academic perspective on metabolic diseases.

Dr. Cho’s clinical and research interests center on diabetes and obesity, with particular emphasis on gut hormones and glucose metabolism. He leads and participates in clinical trials evaluating novel pharmacologic agents, digital health technologies, and medical devices aimed at improving outcomes in patients with metabolic disorders.

Through his multifaceted contributions to clinical care, translational research, and innovation, Dr. Cho continues to play a leading role in advancing the understanding and treatment of diabetes, obesity, and related endocrine disorders.

GLP-1은 어떻게 슈퍼호르몬이 되었나?

How GLP-1 Became a Superhormone?

학습목표(Learning Objectives)

1. GLP-1의 다면적 작용 기전 이해: GLP-1이 혈당 조절, 식욕 억제, 위 배출 지연 등 인체 대사 조절에 미치는 다양한 생리학적 메커니즘을 설명할 수 있다.

2. GLP-1 기반 치료제의 임상적 활용 범위 파악: GLP-1 수용체 작용제가 2형 당뇨병 및 비만 치료를 넘어 심혈관 질환, 신장 질환, 지방간 등의 만성 질환에 어떻게 적용되는지 파악할 수 있다.

3. GLP-1의 새로운 치료 영역 및 미래 전망 논의: 신경 퇴행성 질환, 수면 무호흡증, 중독 치료 등GLP-1의 잠재적이고 새로운 치료 영역과 경구용, 장기 지속형, 다중 호르몬 타깃팅 등 최신 약제 개발 동향을 논의할 수 있다.

1. Understand the Multifaceted Mechanisms of GLP-1: Be able to explain the diverse physiological mechanisms by which GLP-1 regulates human metabolism, including glycemic control, appetite suppression, and delayed gastric emptying.

2. Identify Clinical Applications of GLP-1-Based Therapies: Be able to identify how GLP-1 receptor agonists are applied in chronic diseases such as cardiovascular disease, kidney disease, and fatty liver disease, beyond type 2 diabetes and obesity treatment.

3. Discuss Emerging Therapeutic Areas and Future Prospects of GLP-1: Be able to discuss potential new therapeutic areas for GLP-1, such as neurodegenerative diseases, sleep apnea, and addiction treatment, as well as the latest drug development trends including oral, long-acting and multi-hormone targeting.

초록(Abstract)

장 호르몬 시대의 도래와 함께 글루카곤유사펩티드-1(GLP-1)은 당뇨병 치료제를 넘어 슈퍼호르몬으로 부상하며 의학계에 혁명적인 변화를 가져왔다. 본 강의에서는 GLP-1의 발견부터 현재에 이르기까지 그 여정을 심층적으로 탐구해 보고자 한다. GLP-1은 소장 내분비세포에서 분비되어 혈당 의존적으로 인슐린 분비를 촉진하고, 글루카곤 분비를 억제하며, 위 배출을 지연시키고, 중추신경계에 작용하여 식욕을 억제하며 포만감을 증대시키는 다각적인 작용 기전을 가진다. 삭센다, 위고비, 마운자로와 같은 GLP-1 기반 약제들은 비만 치료에서 전례 없는 체중 감량 효과(15~20%)를 입증하였고, 이는 2형 당뇨병 환자의 혈당 조절뿐만 아니라 심혈관 질환, 신장 질환, 지방간 등의 만성 질환 관리에도 획기적인 개선을 가져왔다. 나아가 파킨슨병, 알츠하이머병, 수면 무호흡증, 알코올 중독 치료에 대한 잠재적 효과까지 보고되고 있어 그 치료 영역이 무궁무진하게 확장되고 있다. 이번 강의에서 GLP-1의 과학적 배경, 임상적 적용, 그리고 최신 개발 동향(경구용, 장기 지속형, 다중 호르몬 타깃팅 등)을 상세히 다루어, 의료 전문가들이 GLP-1 호르몬의 현재와 미래*를 이해하고 환자 치료에 적용할 수 있는 통찰력을 제공하고자 한다.

With the advent of the gut hormone era, Glucagon-Like Peptide-1 (GLP-1) has emerged as a “superhormone”, revolutionizing medicine beyond its initial role in diabetes treatment. This lecture explores GLP-1's journey from its discovery to its current state. GLP-1, secreted by intestinal endocrine cells, exhibits multifaceted mechanisms of action: it stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and acts on the central nervous system to inhibit appetite and enhance satiety. GLP-1-based medications such as Saxenda, Wegovy, and Mounjaro have demonstrated unprecedented weight loss effects (15-20%) in obesity treatment. This has led to remarkable improvements not only in glycemic control for type 2 diabetes patients but also in the management of chronic conditions like cardiovascular disease, kidney disease, and fatty liver disease. Furthermore, potential therapeutic effects are being reported for Parkinson's disease, Alzheimer's disease, sleep apnea, and alcohol use disorder, indicating an extensive expansion of its therapeutic scope. This lecture will detail the scientific background, clinical applications, and latest development trends (oral formulations, long-acting injectables, multi-hormone targeting, etc.) of GLP-1. It aims to provide medical professionals with insights to understand the present and future of this powerful hormone and apply it to patient care.

(MD, PhD)